Jiangsu Hengrui Medicine has been granted a patent for a LAG-3 antibody and its antigen-binding fragments, aimed at treating tumors by inhibiting their growth. The patent includes a method for administering these antibodies, which feature specific complementarity determining regions for enhanced efficacy. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of June 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Lag-3 antibody for inhibiting tumor cell growth
The granted patent US11981733B2 outlines a method for inhibiting tumor cell growth in subjects through the administration of an anti-LAG-3 antibody or its antigen-binding fragment. The claims specify that the antibody must contain particular heavy and light chain variable regions characterized by specific complementarity determining regions (CDRs). These regions are defined by sequences listed as SEQ ID NO: 7 and SEQ ID NO: 8, with additional claims detailing the identity and variations of these sequences. The method is applicable to subjects with diseases associated with LAG-3, including a wide range of cancers such as ovarian, melanoma, prostate, and breast cancer, among others.
Further claims elaborate on the structural components of the anti-LAG-3 antibody, including the potential for murine, chimeric, or humanized forms. The patent specifies that the heavy and light chain variable regions can be selected from various sequences, with an emphasis on maintaining a certain percentage of identity to the specified sequences. Additionally, the claims address the constant regions of the antibody, which can be derived from different murine or human immunoglobulin classes. The patent ultimately provides a comprehensive framework for the development of anti-LAG-3 antibodies aimed at treating cancer, highlighting the specificity of the sequences involved and their potential therapeutic applications.
To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
